Beam Therapeutics
IPO News: Filed S-1/A: Beam Therapeutics Launches 6.3mm Share IPO with $15.00 - $17.00 Marketing Range
Beam Therapeutics

Beam Therapeutics

NASDAQ:  BEAM

Initial Filing Date:  09/27/19

Launch Date:  01/27/20

Price Range:  $15.00 - $17.00

Shares Offered (Pre-Shoe | mm):  6.3

Primary Shares (mm):  6.3

Secondary Shares (mm):  0.0

Amount Offered (@ Midpoint)(mm):  $100.0

% Secondary:  0.0%

Shares Outstanding (mm):  45.3

Market Value at Midpoint (mm):  $725.2

Offering as % of Market Value:  13.8%

Bookrunners:  JP Morgan | Jefferies | Barclays

Co-Managers: Wedbush

Major Holders:  ARCH Venture Partners | F-Prime Capital Partners | HH Beam Holdings | Executives and Directors (Co-Founders, David Liu and Feng Zhang)

Description:  Beam is a biotechnology company committed to creating a new class of precision genetic medicines based on their proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases.

Note:  Emerging Growth Company

Reference Link:  S-1/A